Precigen (PGEN) Other Non-Current Assets (2012 - 2026)
Precigen (PGEN) posted quarterly Other Non-Current Assets of $782000.0 for Q1 2026, up 83.14% year-over-year from $427000.0 in Q1 2025, and down 13.88% quarter-over-quarter from $908000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Other Non-Current Assets for 15 consecutive years, with $782000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 83.14% year-over-year to $782000.0; the TTM figure through Mar 2026 stood at $782000.0 (up 83.14% YoY), while the FY2025 annual figure was $908000.0, up 144.74% from the prior year.
- Other Non-Current Assets declined to $782000.0 in Q1 2026 per PGEN's latest filing, from $908000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $44.3 million in Q2 2022 and bottomed at $371000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $3.5 million across 5 years, with a median of $774500.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 402990.91% — and 2023, when it sank 97.86%.
- Precigen's Other Non-Current Assets stood at $1.0 million in 2022, then retreated by 25.17% to $767000.0 in 2023, then plunged by 51.63% to $371000.0 in 2024, then surged by 144.74% to $908000.0 in 2025, then dropped by 13.88% to $782000.0 in 2026.
- Business Quant data shows PGEN's Other Non-Current Assets at $782000.0 in Q1 2026, $908000.0 in Q4 2025, and $753000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 708,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 708,000.00 |
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 908,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 590,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 371,000.00 |
| Sep 30, 2024 | 425,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 767,000.00 |
| Sep 30, 2023 | 797,000.00 |
| Jun 30, 2023 | 949,000.00 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 871,000.00 |
| Jun 30, 2022 | 44.57 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 45.30 Mn |
| Sep 30, 2021 | 1.24 Mn |